You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):SYS6045(抗體藥物偶聯物)獲臨牀試驗批准
格隆匯 01-07 17:35

格隆匯1月7日丨石藥集團(01093.HK)發佈公吿,集團開發的SYS6045(抗體藥物偶聯物)已獲中國國家藥品監督管理局批准,可以在中國開展臨牀試驗。

該產品為一款單克隆抗體藥物偶聯物,可與腫瘤表面的特異性受體結合,通過內吞作用進入細胞並釋放毒素,達到殺傷腫瘤細胞的作用。該產品按照治療用生物製品1類申報,本次獲批的適應症為晚期實體瘤,預計適用於治療乳腺癌、胃癌、子宮內膜癌、宮頸癌、結直腸癌等。臨牀前研究顯示該產品對多種癌症均有較好的抗腫瘤作用,具備較高的臨牀開發價值。該產品已在國內外提交多項專利申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account